Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
WuXi AppTec hosted an inaugural Global Monoclonal Antibody Summit in conjunction with the startup of its cGMP biologics manufacturing facility in the city of Wuxi on October 10-12, 2012. Attending the event were executives from global pharmaceutical ...
read more
WuXi AppTec announced the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines.
read more
Tuesday, October 19, 2021
WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai.
read more
Wednesday, September 21, 2022
WuXi Biologics announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
read more
Tuesday, February 12, 2019
WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
read more
Wednesday, August 23, 2017
WuXi Biologics announces its unaudited interim results for the six months ended June 30, 2017.
read more
Wednesday, October 31, 2018
WuXi Biologics announced that construction has commenced on a Biologics Manufacturing Center of excellence (MFG8), in the city of Shijiazhuang, one hour train from Beijing.
read more
Monday, November 01, 2021
WuXi Biologics a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product ...
read more
WuXi Biologics has received EMA GMP certificates for the production of Trogarzo™ at its cGMP DS and DP manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai.
read more
Wednesday, February 09, 2022
We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022.
read more
Friday, February 14, 2020
WuXi Biologics has released the following statement addressing the Coronavirus outbreak.
read more
WuXi Biologics has entered into a strategic partnership LOI with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
read more
Wednesday, March 21, 2018
WuXi Biologics has selected 4,000 liter (L) Custom Single Run (CSR) disposable bioreactors from ABEC for its new commercial manufacturing facility (MFG4) in Wuxi city, Jiangsu, China.
read more
WuXi Biologics and Immune Pharmaceuticals announced a development and manufacturing agreement for the production of bertilimumab, Immune's first-in-class anti-eotaxin-1 monoclonal antibody.
read more
Wednesday, December 02, 2020
WuXi Advanced Therapies announced the completion of a facility expansion that will triple its advanced testing capacity at the company's Philadelphia Navy Yard campus.
read more